fosamax femur fracture lawsuit
Patients and healthcare pros may possibly have concerns about oral bisphosphonate medicines and atypical subtrochanteric femur fractures &ndash fractures in the bone just beneath the hip joint. Oral bisphosphonates are typically prescribed to stop or treat osteoporosis in postmenopausal females. Common brand names of medicines in this class incorporate Fosamax, Actonel, Boniva, and Reclast. If you have taken fosamax you should speak to your health care provider to see if you are at risk for a fosamax femur fracture.
Recent news reports have raised the question about no matter whether there is an elevated risk of this kind of fracture in patients with osteoporosis using these medications. At this point, the information that FDA has reviewed have not shown a clear connection in between bisphosphonate use and a risk of atypical subtrochanteric femur fractures. FDA is operating closely with outside specialists, such as members of the lately convened American Society of Bone and Mineral Study Subtrochanteric Femoral Fracture Job Force, to gather further data that might give a lot more insight into this issue.
Based on published case reports of atypical subtrochanteric femur fractures occurring in females with osteoporosis making use of bisphosphonates, FDA, in June 2008, requested info from all bisphosphonate drug producers regarding this possible safety signal. All obtainable case reports and clinical trial information were requested. FDA’s evaluation of these data did not show an improve in this threat in females employing these medicines.
In addition, FDA reviewed a December 2008 article in the Journal of Bone and Mineral Study by Abrahamsen et al1, that analyzed information from two large observational studies in patients with osteoporosis. The authors concluded that atypical subtrochanteric femur fractures had numerous comparable functions in typical with classical osteoporotic hip fractures, which includes patient age, gender, and trauma mechanism. The data showed that patients taking bisphosphonates and those not taking bisphosphonates had related numbers of atypical subtrochanteric femur fractures relative to classical osteoporotic hip fractures. If you or someone you know has suffered a femur fracture after taking Fosamax, you or they may be eligible for a fosamax femur fracture lawsuit.
This communication is in keeping with FDA’s commitment to inform the public about its ongoing safety evaluation of drugs. The agency will continue to assessment new information as it becomes obtainable and will update the public as soon as the agency’s review is complete.
Healthcare specialists should continue to follow the suggestions in the drug label when prescribing oral bisphosphonates. Patients really should not stop taking their medication unless told to do so by their healthcare skilled. Patients should talk to their healthcare skilled about any concerns they have with these medicines.